Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion aims to develop a […]
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial met its primary endpoint with Nefecon demonstrating a highly […]
Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI Decreasing glutamate adds to the previously reported reduction in […]
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 fold Modi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant […]